MRK Merck & Co (MRK) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0000310158
Congress · 3Form 144 · 9
Insider buyers, 180 days
0
Funds added, last quarter
1,858
13F, latest reported quarter
Conversions, 180 days
12
Codes C/M, not in net · $12.9M priced
What the filings say about MRK
Insiders, 180 days
-$30.0M net sold
5 sellers · 0% of sales under a 10b5-1 plan
Congress, 1 year
3 bought · 2 sold
Latest: sale, 2026-09-24
Planned sales (Form 144), 90 days
$30.0M
9 notices
Merck & Co insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, Merck & Co., Inc. insiders sold a net $30.0M of stock across 129 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-27.
Insider
Filed
Shares
Value
Since filing
Context
- 4 earlier Form 4 trades (code P or S) here by this insider (4 sales), the last on Aug 6, 2026.
- The trade is 27.3% of the 36,613 shares held after it.
- 4 other insiders sold within 30 days.
- 1,858 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: EVP, Access, Policy & Comms Guindo Chirfi sold about $1.4M of MRK on Aug 13, 2026; 4 other insiders sold within 30 days and 1,858 funds added in the latest 13F quarter.Context
- 13 earlier Form 4 trades (code P or S) here by this insider (13 sales), the last on Aug 11, 2026.
- The trade is 10.0% of the 110,767 shares held after it.
- 4 other insiders sold within 30 days.
- 1,858 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: EVP&Pres, Merck Animal Heallth DeLuca Richard R. sold about $1.5M of MRK on Aug 12, 2026; 4 other insiders sold within 30 days and 1,858 funds added in the latest 13F quarter.Context
- 13 earlier Form 4 trades (code P or S) here by this insider (13 sales), the last on Aug 11, 2026.
- The trade is 0.5% of the 110,167 shares held after it.
- 4 other insiders sold within 30 days.
- 1,858 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: EVP&Pres, Merck Animal Heallth DeLuca Richard R. sold about $79.2K of MRK on Aug 12, 2026; 4 other insiders sold within 30 days and 1,858 funds added in the latest 13F quarter.Context
- 8 earlier Form 4 trades (code P or S) here by this insider (8 sales), the last on Feb 9, 2026.
- The trade is 176.5% of the 45,509 shares held after it.
- 4 other insiders sold within 30 days.
- 1,858 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: EVP, General Counsel Zachary Jennifer sold about $10.7M of MRK on Aug 12, 2026, the largest insider sale at the company since 2024; 4 other insiders sold within 30 days and 1,858 funds added in the latest 13F quarter.Context
- 11 earlier Form 4 trades (code P or S) here by this insider (11 sales), the last on Aug 10, 2026.
- The trade is 5.8% of the 127,293 shares held after it.
- 4 other insiders sold within 30 days.
- 1,858 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: EVP&Pres, Merck Animal Heallth DeLuca Richard R. sold about $973.2K of MRK on Aug 11, 2026; 4 other insiders sold within 30 days and 1,858 funds added in the latest 13F quarter.129 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$30.0M over 180 days
-$30.0M over 90 days
below 91% of Pharma & Biotech
Congress
3 members bought in the last year
more than 90% of Pharma & Biotech
Funds
1,858 funds bought in last quarter
the highest in Pharma & Biotech
Revenue
+1.3% year over year
below 51% of Pharma & Biotech
Margin
28.1% net margin
more than 89% of Pharma & Biotech
Buybacks
$1.6B repurchased, FY to 2026-06-30
more than 97% of Pharma & Biotech
Short interest
1.1% of the float short (float per yahoo 2026-10-26) · 2.5 days to cover · settled 2026-09-30
below 72% of Pharma & Biotech
The situation: each line is one rule over one dataset
10 clinical trials were terminated, suspended or withdrawn in the last 90 days.
What changed in the last 30 days
Oct 7Rep. Maria Elvira Salazar sold $1.0K to $15K, disclosed 13 days after the trade
Why it matters
House members report a bracket, not an exact amount, and have 45 days to do it; the trade is weeks old when it becomes public.
Watch MRK
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+69.7%12M
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns MRK: institutional holders (13F)
13F holdings, latest reported quarter
226,999,837 sh
$29.2B
161,323,174 sh
$20.7B
120,413,256 sh
$15.6B
86,249,283 sh
$11.1B
67,738,969 sh
$8.7B
Congress trades in MRK
STOCK Act disclosures, US House only, filed up to 45 days after the trade
Sold 2026-09-24 · disclosed 13 days later
$1,001 - $15,000
Bought 2026-08-19 · disclosed 21 days later
$15,001 - $50,000
Bought 2026-02-04 · disclosed 40 days later
$1,001 - $15,000
Bought 2025-12-19 · disclosed 24 days later
$1,001 - $15,000
Sold 2025-12-18 · disclosed 28 days later
$1,001 - $15,000
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
MRK planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
CHIRFI GUINDO
Filed 2026-08-13
$1.4M
RICHARD ROBERT DELUCA JR
Filed 2026-08-12
$1.5M
JENNIFER L ZACHARY
Filed 2026-08-12
$10.7M
RICHARD ROBERT DELUCA JR
Filed 2026-08-11
$1.7M
RICHARD ROBERT DELUCA JR
Filed 2026-08-10
$2.7M
MRK mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
VanEck Pharmaceutical ETF
$86.6M position · as of 2026-06-30
9.8%
Hennessy Total Return Fund
$3.9M position · as of 2026-07-31
7.7%
First Trust Nasdaq Pharmaceuticals ETF
$2.6M position · as of 2026-06-30
7.1%
HARTFORD HEALTHCARE HLS FUND
$7.4M position · as of 2026-06-30
6.6%
Northern Trust US Equity ETF
$55.2M position · as of 2026-06-30
6.3%
BRUCE FUND
$23.1M position · as of 2026-06-30
6.2%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
664 registered trials, 227 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
218
Phase 1
31 active
132
Phase 2
53 active
236
Phase 3
98 active
9
Phase 4
2 active
1
Early Phase 1
0 active
6
Not applicable
2 active
62
Multi-phase
41 active
What changed recently
Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Gue
2026-10-24 · Completion moved 2026-07-31 → 2028-07-31
Phase 3
A Study of V118E in Healthy Participants (V118E-003)
2026-10-24 · Recruiting → Active Not Recruiting
Phase 1
A Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (PAH) in
2026-10-23 · Not Yet Recruiting → Recruiting
Phase 4
A Clinical Study of V503 in Chinese Females Who Have Previously Received a Bivalent Huma
2026-10-23 · Not Yet Recruiting → Recruiting
Phase 3
A Clinical Study of Enlicitide (MK-0616) in Adults With Hyperlipidemia in India (MK-0616
2026-10-23 · Not Yet Recruiting → Recruiting
Phase 3
Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Po
2026-10-22 · Completion moved 2030-04-18 → 2032-08-02
PHASE1,PHASE2
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Government contracts
Award ceilings over the contract's life, subsidiaries included.
Not annual revenue (USASpending.gov).
Department Of Health And Human Services
IGF::OT::IGF · 2017-09-28
$236.3M
Department Of Health And Human Services
ERVEBO PROCUREMENT · 2024-09-30
$156.0M
Federal awards ≥ $25M in the last 90 days, matched via the SAM.gov parent registry
Corporate PAC
The company's PAC: committee totals only, never individual donors (FEC).
Merck & Co., Inc., Employees Political Action Committee (Merck Pac)
Cycle 2026 · $980K spent
$1.1M
Federal Election Commission, matched by the PAC's connected organisation
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $30.0M sold by insiders over 180 days, 1,858 funds added last quarter, 3 House member(s) bought in 12 months, disclosed weeks after the trade, $30.0M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
MRK financials
Revenue growth
+1.3%
XBRL, annual
Net margin
28.1%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$66.6B
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM MRK
| FY Dec 2025 | $65.0B |
| FY Dec 2024 | $64.2B |
| FY Dec 2023 | $60.1B |
| FY Dec 2022 | $59.3B |
| FY Dec 2021 | n/a |
| Jun 2026 | $16.6B |
| Mar 2026 | $16.3B |
| Dec 2025 | $16.4B |
| Sep 2025 | $17.3B |
| Jun 2025 | $15.8B |
| Mar 2025 | $15.5B |
| Dec 2024 | $15.6B |
| Sep 2024 | $16.7B |
At each fiscal year end
Single quarter
Net margin, TTM
+4.8%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM MRK
| FY Dec 2025 | +28.1% |
| FY Dec 2024 | +26.7% |
| FY Dec 2023 | +0.6% |
| FY Dec 2022 | +24.5% |
| FY Dec 2021 | n/a |
| Jun 2026 | -8.0% |
| Mar 2026 | -26.0% |
| Dec 2025 | +18.1% |
| Sep 2025 | +33.5% |
| Jun 2025 | +28.0% |
| Mar 2025 | +32.7% |
| Dec 2024 | +24.0% |
| Sep 2024 | +19.0% |
At each fiscal year end
Single quarter
Free cash flow, TTM
$16.1B
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM MRK
| FY Dec 2025 | $12.4B |
| FY Dec 2024 | $18.1B |
| FY Dec 2023 | $9.1B |
| FY Dec 2022 | $14.7B |
| FY Dec 2021 | $6.9B |
| Jun 2026 | $4.5B |
| Mar 2026 | $2.9B |
| Dec 2025 | $1.8B |
| Sep 2025 | $6.8B |
| Jun 2025 | $2.5B |
| Mar 2025 | $1.2B |
| Dec 2024 | $2.5B |
| Sep 2024 | $8.5B |
At each fiscal year end
Single quarter
Debt to equity
1.29x
long-term 2026-06-30 plus current 2026-06-30; equity 2026-06-30
Debt to equity MRK
| FY Dec 2025 | 0.94x |
| FY Dec 2024 | 0.80x |
| FY Dec 2023 | 0.93x |
| FY Dec 2022 | 0.67x |
| FY Dec 2021 | 0.87x |
| Jun 2026 | 1.29x |
| Mar 2026 | 1.07x |
| Dec 2025 | 0.94x |
| Sep 2025 | 0.80x |
| Jun 2025 | 0.72x |
| Mar 2025 | 0.72x |
| Dec 2024 | 0.80x |
| Sep 2024 | 0.86x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
0.37x
TTM operating cash flow over long-term 2026-06-30 plus current 2026-06-30
Cash flow to debt MRK
| FY Dec 2025 | 0.33x |
| FY Dec 2024 | 0.58x |
| FY Dec 2023 | 0.37x |
| FY Dec 2022 | 0.62x |
| FY Dec 2021 | 0.34x |
| Jun 2026 | 0.37x |
| Mar 2026 | 0.36x |
| Dec 2025 | 0.33x |
| Sep 2025 | 0.41x |
| Jun 2025 | 0.52x |
| Mar 2025 | 0.60x |
| Dec 2024 | 0.58x |
| Sep 2024 | 0.48x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
+7.0%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity MRK
| FY Dec 2025 | +36.9% |
| FY Dec 2024 | +40.8% |
| FY Dec 2023 | +0.9% |
| FY Dec 2022 | +34.5% |
| FY Dec 2021 | +38.9% |
| Jun 2026 | +7.0% |
| Mar 2026 | +19.0% |
| Dec 2025 | +36.9% |
| Sep 2025 | +39.5% |
| Jun 2025 | +35.4% |
| Mar 2025 | +39.3% |
| Dec 2024 | +40.8% |
| Sep 2024 | +28.3% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
+2.6%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets MRK
| FY Dec 2025 | +14.4% |
| FY Dec 2024 | +15.3% |
| FY Dec 2023 | +0.3% |
| FY Dec 2022 | +13.5% |
| FY Dec 2021 | +12.5% |
| Jun 2026 | +2.6% |
| Mar 2026 | +7.3% |
| Dec 2025 | +14.4% |
| Sep 2025 | +15.4% |
| Jun 2025 | +14.3% |
| Mar 2025 | +15.8% |
| Dec 2024 | +15.3% |
| Sep 2024 | +10.8% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
fewer than four consecutive quarters of operating income
Return on invested capital MRK
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
n/a
fewer than four consecutive quarters of operating income
Return on capital employed MRK
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
115.29x
close 2026-10-23 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
P/E, trailing MRK
| FY Dec 2025 | 14.44x |
| FY Dec 2024 | 14.78x |
| FY Dec 2023 | 778.71x |
| FY Dec 2022 | 19.43x |
| FY Dec 2021 | 14.91x |
| Jun 2026 | 101.98x |
| Mar 2026 | 33.79x |
| Dec 2025 | 14.44x |
| Sep 2025 | 11.09x |
| Jun 2025 | 12.20x |
| Mar 2025 | 13.07x |
| Dec 2024 | 14.78x |
| Sep 2024 | 23.81x |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$405.5B
market value at close 2026-10-23 on 2026-07-31 shares, plus long-term 2026-06-30 plus current 2026-06-30, minus cash 2026-06-30
Enterprise value MRK
| FY Dec 2025 | $296.0B |
| FY Dec 2024 | $275.5B |
| FY Dec 2023 | $304.5B |
| FY Dec 2022 | $299.3B |
| FY Dec 2021 | $218.6B |
| Jun 2026 | $364.4B |
| Mar 2026 | $341.2B |
| Dec 2025 | $296.0B |
| Sep 2025 | $232.8B |
| Jun 2025 | $226.2B |
| Mar 2025 | $253.0B |
| Dec 2024 | $275.5B |
| Sep 2024 | $311.4B |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
+4.5%
TTM free cash flow over market value at close 2026-10-23
FCF yield MRK
| FY Dec 2025 | +4.7% |
| FY Dec 2024 | +7.2% |
| FY Dec 2023 | +3.3% |
| FY Dec 2022 | +5.2% |
| FY Dec 2021 | +3.6% |
| Jun 2026 | +5.1% |
| Mar 2026 | +4.7% |
| Dec 2025 | +4.7% |
| Sep 2025 | +6.2% |
| Jun 2025 | +7.4% |
| Mar 2025 | +7.5% |
| Dec 2024 | +7.2% |
| Sep 2024 | +5.2% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing EPS growth -81%, PEG needs growth
PEG, trailing MRK
| FY Dec 2025 | 1.74x |
| FY Dec 2024 | 0.00x |
| FY Dec 2023 | n/a |
| FY Dec 2022 | 1.75x |
| FY Dec 2021 | 0.17x |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | 1.74x |
| Sep 2025 | 0.19x |
| Jun 2025 | 0.60x |
| Mar 2025 | 0.02x |
| Dec 2024 | 0.00x |
| Sep 2024 | 0.14x |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-23. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $65.0B | $64.2B | $60.1B | $59.3B |
| Net income | $18.3B | $17.1B | $365.0M | $14.5B |
| EPS (diluted) | 7.28 | 6.74 | 0.14 | 5.71 |
| Operating cash flow | $16.5B | $21.5B | $13.0B | $19.1B |
| Cash | $14.6B | $13.2B | $6.8B | $12.7B |
| Long-term debt | $46.8B | $34.5B | $33.7B | $28.7B |
| Buybacks | $5.1B | $1.3B | $1.3B | $0 |
| Dividends paid | $8.2B | $7.8B | $7.4B | $7.0B |
SEC XBRL, fiscal years, as known on 2026-10-27
MRK Stock Sonar score 6/7 axes
Find similar shapesCompareMRK ranks highest on institutional and government (86th percentile) and profitability (83rd), and lowest on insider conviction (3rd), among Pharma & Biotech peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
MRK filings, in plain words
Are Merck & Co insiders buying or selling MRK?
In the 180 days to 2026-10-27, Merck & Co insiders were net sellers, a net $30.0M across purchases and sales reported on Form 4, by 5 sellers.
Have members of Congress traded MRK?
Yes. In the year to 2026-10-27, 3 House members disclosed buying MRK and 2 House members disclosed selling it; the latest on record is a sale by Maria Elvira Salazar dated 2026-09-24.
Are there planned insider sales of MRK?
Yes. 9 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-27, covering $30.0M of stock; the latest, by CHIRFI GUINDO, was filed 2026-08-13.
Read the full summary
In the 180 days to 2026-10-27, Merck & Co insiders were net sellers of MRK, a net $30.0M across purchases and sales reported on Form 4 by 5 sellers. None of the 17 insider sales was flagged as made under a Rule 10b5-1 plan. In the year to 2026-10-27, 3 members of Congress disclosed buying MRK and 2 members disclosed selling it; the latest on record is a sale by Maria Elvira Salazar dated 2026-09-24. Insiders filed 9 Form 144 notices of intent to sell in the 90 days to 2026-10-27, covering $30.0M of stock. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
